Xvivo Perfusion AB Market Cap ($694.92 Million)
Market Cap & Net Worth: Xvivo Perfusion AB (XVIVO)
Xvivo Perfusion AB market cap. Xvivo Perfusion AB (ST:XVIVO) has a market capitalization of $694.92 Million (Skr6.46 Billion) as of November 1, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #10233 globally and #174 in its home market, demonstrating a -8.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xvivo Perfusion AB's stock price Skr205.00 by its total outstanding shares 31499470 (31.50 Million). Also see Xvivo Perfusion AB operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Xvivo Perfusion AB Market Cap History (2015–2026)
Xvivo Perfusion AB market cap history from 2015 to 2026. Data shows growth from $198.31 Million to $694.92 Million (13.38% CAGR). Check Xvivo Perfusion AB stock price for real-time trading data and today's change.
Xvivo Perfusion AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xvivo Perfusion AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore XVIVO net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.78x
Xvivo Perfusion AB's market cap is 0.78 times its annual revenue
Latest Price to Earnings (P/E) Ratio
25.14x
Xvivo Perfusion AB's market cap is 25.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $298.31 Million | $138.18 Million | $1.50 Million | 2.16x | 198.74x |
| 2017 | $318.65 Million | $148.34 Million | $6.26 Million | 2.15x | 50.90x |
| 2018 | $447.46 Million | $187.87 Million | $12.69 Million | 2.38x | 35.27x |
| 2019 | $576.27 Million | $220.84 Million | $4.94 Million | 2.61x | 116.68x |
| 2020 | $1.06 Billion | $179.86 Million | -$43.73 Million | 5.92x | N/A |
| 2021 | $944.07 Million | $258.39 Million | $8.15 Million | 3.65x | 115.81x |
| 2022 | $620.34 Million | $415.29 Million | $18.43 Million | 1.49x | 33.66x |
| 2023 | $1.12 Billion | $597.54 Million | $91.82 Million | 1.87x | 12.16x |
| 2024 | $1.66 Billion | $822.41 Million | $172.18 Million | 2.02x | 9.63x |
| 2025 | $632.55 Million | $812.16 Million | $25.16 Million | 0.78x | 25.14x |
Competitor Companies of XVIVO by Market Capitalization
Companies near Xvivo Perfusion AB in the global market cap rankings as of November 1, 2026. Also see Xvivo Perfusion AB (XVIVO) total assets for a full breakdown of the balance sheet.
Key companies related to Xvivo Perfusion AB by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #114 globally with a market cap of $184.67 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #215 globally with a market cap of $111.95 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #225 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #241 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #114 | Abbott Laboratories | NYSE:ABT | $184.67 Billion | $106.20 |
| #215 | Stryker Corporation | NYSE:SYK | $111.95 Billion | $291.86 |
| #225 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $96.54 |
| #241 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Xvivo Perfusion AB (2015–2026)
Market capitalization of Xvivo Perfusion AB from 2015 to today. Between 2015 and today, Xvivo Perfusion AB's market cap moved from $198.31 Million to $ 694.92 Million, with a yearly change of 13.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr694.92 Million | +9.86% |
| 2025 | Skr632.55 Million | -61.84% |
| 2024 | Skr1.66 Billion | +48.41% |
| 2023 | Skr1.12 Billion | +80.05% |
| 2022 | Skr620.34 Million | -34.29% |
| 2021 | Skr944.07 Million | -11.31% |
| 2020 | Skr1.06 Billion | +84.71% |
| 2019 | Skr576.27 Million | +28.79% |
| 2018 | Skr447.46 Million | +40.43% |
| 2017 | Skr318.65 Million | +6.82% |
| 2016 | Skr298.31 Million | +50.43% |
| 2015 | Skr198.31 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Xvivo Perfusion AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $694.92 Million USD |
| MoneyControl | $694.92 Million USD |
| MarketWatch | $694.92 Million USD |
| marketcap.company | $694.92 Million USD |
| Reuters | $694.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more